no not until later in the year and based on no further grants from dod usa but wouldnt rule that out
further phase 3 Indonesian trial on diabetic ulcers not cash flow draining as mostly paid for by them
further r&d rebates due also to boost cash kitty before june so in. My view this release on absssi trials is not a fluff and pump as a precursor to a cap raise
but what would i know anyway
Add to My Watchlist
What is My Watchlist?
